Keywords: Pfizer, Lyrica, Seizure frequency, Epilepsy, Fibromyalgia, Ph III

Pfizer's Lyrica misses primary endpoint in seizure frequency trial; positive in fibromyalgia

Article | 20 November 2012

US pharma behemoth Pfizer (NYSE: PFE) revealed disappointing top-line results of a double-blind, placebo-controlled, Phase III study evaluating both the 165 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Pfizer

Go to company listing

Related Drugs

Lyrica

Go to drug listing